Cargando…
Primary Cardiac Allograft Dysfunction—Validation of a Clinical Definition
BACKGROUND: Heart transplantation is an established treatment for advanced heart failure. Primary allograft dysfunction (PGD) is reported in up to 40% of transplants and is associated with a poor outcome. METHODS: As part of Heart Evaluation and Retrieval for Transplantation study, an investigation...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4548546/ https://www.ncbi.nlm.nih.gov/pubmed/25742423 http://dx.doi.org/10.1097/TP.0000000000000620 |
_version_ | 1782387209763028992 |
---|---|
author | Dronavalli, Vamsidhar B. Rogers, Chris A. Banner, Nicholas R. |
author_facet | Dronavalli, Vamsidhar B. Rogers, Chris A. Banner, Nicholas R. |
author_sort | Dronavalli, Vamsidhar B. |
collection | PubMed |
description | BACKGROUND: Heart transplantation is an established treatment for advanced heart failure. Primary allograft dysfunction (PGD) is reported in up to 40% of transplants and is associated with a poor outcome. METHODS: As part of Heart Evaluation and Retrieval for Transplantation study, an investigation of the assessment of donor hearts for transplantation, we proposed a clinical definition for cardiac PGD comprising severely impaired systolic function affecting one or both ventricles accompanied by hypotension, low cardiac output, and high filling pressures occurring in the first 72 hours (in the absence of hyper acute rejection and technical surgical factors, such as cardiac tamponade). Here, we examine the prospective application of this definition to 290 heart transplants. We compared the clinical outcome of PGD and non-PGD cases. RESULTS: Ninety-four of 290 transplants developed PGD (32.4%). Inotrope use (score) was higher in the PGD group at 24, 48, and 72 hours after transplantation (P < 0.01). In the PGD group, there was a greater requirement for, intra-aortic balloon pump (50% vs 15%, P < 0.01), mechanical support (27% vs 0%, P < 0.01), and renal replacement therapy (61% vs 26%, P < 0.01). Intensive care stay was longer for recipients with PGD (median 14 vs 5 days, P < 0.01) and early mortality was higher (37% vs 4% at 30 days, 42% vs 8% at 1 year, P < 0.01). CONCLUSIONS: In conclusion, our definition of PGD could be applied in a national multicenter study, and the cases it defined had more frequent complications and higher mortality. |
format | Online Article Text |
id | pubmed-4548546 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-45485462015-09-09 Primary Cardiac Allograft Dysfunction—Validation of a Clinical Definition Dronavalli, Vamsidhar B. Rogers, Chris A. Banner, Nicholas R. Transplantation Original Clinical Science—General BACKGROUND: Heart transplantation is an established treatment for advanced heart failure. Primary allograft dysfunction (PGD) is reported in up to 40% of transplants and is associated with a poor outcome. METHODS: As part of Heart Evaluation and Retrieval for Transplantation study, an investigation of the assessment of donor hearts for transplantation, we proposed a clinical definition for cardiac PGD comprising severely impaired systolic function affecting one or both ventricles accompanied by hypotension, low cardiac output, and high filling pressures occurring in the first 72 hours (in the absence of hyper acute rejection and technical surgical factors, such as cardiac tamponade). Here, we examine the prospective application of this definition to 290 heart transplants. We compared the clinical outcome of PGD and non-PGD cases. RESULTS: Ninety-four of 290 transplants developed PGD (32.4%). Inotrope use (score) was higher in the PGD group at 24, 48, and 72 hours after transplantation (P < 0.01). In the PGD group, there was a greater requirement for, intra-aortic balloon pump (50% vs 15%, P < 0.01), mechanical support (27% vs 0%, P < 0.01), and renal replacement therapy (61% vs 26%, P < 0.01). Intensive care stay was longer for recipients with PGD (median 14 vs 5 days, P < 0.01) and early mortality was higher (37% vs 4% at 30 days, 42% vs 8% at 1 year, P < 0.01). CONCLUSIONS: In conclusion, our definition of PGD could be applied in a national multicenter study, and the cases it defined had more frequent complications and higher mortality. Lippincott Williams & Wilkins 2015-09 2015-09-02 /pmc/articles/PMC4548546/ /pubmed/25742423 http://dx.doi.org/10.1097/TP.0000000000000620 Text en Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Clinical Science—General Dronavalli, Vamsidhar B. Rogers, Chris A. Banner, Nicholas R. Primary Cardiac Allograft Dysfunction—Validation of a Clinical Definition |
title | Primary Cardiac Allograft Dysfunction—Validation of a Clinical Definition |
title_full | Primary Cardiac Allograft Dysfunction—Validation of a Clinical Definition |
title_fullStr | Primary Cardiac Allograft Dysfunction—Validation of a Clinical Definition |
title_full_unstemmed | Primary Cardiac Allograft Dysfunction—Validation of a Clinical Definition |
title_short | Primary Cardiac Allograft Dysfunction—Validation of a Clinical Definition |
title_sort | primary cardiac allograft dysfunction—validation of a clinical definition |
topic | Original Clinical Science—General |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4548546/ https://www.ncbi.nlm.nih.gov/pubmed/25742423 http://dx.doi.org/10.1097/TP.0000000000000620 |
work_keys_str_mv | AT dronavallivamsidharb primarycardiacallograftdysfunctionvalidationofaclinicaldefinition AT rogerschrisa primarycardiacallograftdysfunctionvalidationofaclinicaldefinition AT bannernicholasr primarycardiacallograftdysfunctionvalidationofaclinicaldefinition |